Table 4.
Complete Response Within Subgroups
| Characteristic | Methotrexate |
Dactinomycin |
||
|---|---|---|---|---|
| No. of Responders/ Total | % | No. of Responders/ Total | % | |
| Age group, years | ||||
| 10-29 | 38/66 | 57.6 | 37/55 | 67.3 |
| 30-39 | 16/31 | 51.6 | 33/41 | 80.5 |
| 40-59 | 3/10 | 30.0 | 6/13 | 46.1 |
| Racial designation | ||||
| White | 40/69 | 58.0 | 50/67 | 74.6 |
| Black | 11/17 | 64.7 | 11/16 | 68.7 |
| All others | 6/21 | 28.6 | 15/26 | 57.7 |
| WHO score | ||||
| 0-1 | 38/54 | 70.4 | 41/51 | 80.4 |
| 2-4 | 18/45 | 40.0 | 31/49 | 63.3 |
| 5-6 | 1/8 | 12.5 | 4/9 | 44.4 |
| Registration βhCG, mIU/mL | ||||
| < 50 | 1/3 | 33.3 | 3/3 | 100.0 |
| 50-99.9 | 2/3 | 66.7 | 3/5 | 60.0 |
| ≥ 100 | 54/101 | 53.5 | 70/101 | 69.3 |
| Registration βhCG, mIU/mL | ||||
| < 5,000 | 37/54 | 68.5 | 42/52 | 80.8 |
| > 5,000 | 20/53 | 37.7 | 34/57 | 59.7 |
| βhCG level change between registration and initiation of treatment | ||||
| Fell | 19/30 | 63.3 | 31/42 | 73.8 |
| Did not fall | 28/54 | 51.8 | 33/52 | 63.5 |
| Registered and treated on the same day | 7/17 | 41.2 | 9/11 | 81.8 |
| Not evaluated on first day of treatment | 3/6 | 50.0 | 3/4 | 75.0 |
| GOG molar classification | ||||
| Partial | 9/17 | 52.9 | 9/12 | 75.0 |
| Complete | 47/81 | 58.0 | 66/94 | 70.2 |
| Choriocarcinoma | 0/7 | 0.0 | 1/3 | 33.3 |
| Indeterminate | 1/2 | 50.0 | 0 | |
| WHO score and histology | ||||
| 0-4 and mole | 56/96 | 58.3 | 71/97 | 73.2 |
| 5-6 or choriocarcinoma | 1/11 | 9.1 | 5/12 | 41.7 |
| Chest CT/chest x-ray results | ||||
| Abnormal/normal | 2/6 | 33.3 | 9/12 | 75.0 |
Abbreviations: βhCG, beta human chorionic gonadotropin; GOG, Gynecologic Oncology Group; CT, computed tomography.